BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:45 PM
 | 
Mar 17, 2008
 |  BC Extra  |  Clinical News

Cardiome reports vernakalant data

Cardiome (TSX:COM; NASDAQ:CRME) was up C$2.02 (32%) to C$8.27 on a newsy Monday. The company released interim data from a Phase IIb trial of oral vernakalant to prevent recurrence of atrial fibrillation (AF) showing that the high dose group has met the primary...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >